Artificial Pancreas Market Research Report- Global Forecast till 2027

Artificial Pancreas Market Research information by control type (threshold suspend device system, non-threshold suspend device system, control-to-range (CTR) system, and control-to-target (CTT) system) by treatment type (insulin only, bi-hormonal, hybrid) and by end users - Global Forecast till 2027

ID: MRFR/MED/2566-HCR | February 2021 | Region: Global | 110 pages

Please note that the assessment period of the report has been updated from 2017-2023 to 2020-2027. Cordially fill Sample form for the updated data.

Market Synopsis of Global Artificial Pancreas Market:


Artificial pancreas are devices that mimics the glucose regulating function of healthy pancreas. These devices use computer-controlled algorithm so as to precisely calculate the amount of insulin to be delivered by using an insulin infusion pump. Advanced products can deliver bi-hormones so as to avoid excessive fall in blood sugar and more closely mimic the working of healthy pancreas with little or no input from the patient.


Considering all these factors the market for Artificial Pancreas is expected to reach USD 360 million by the end of 2023, this market is projected to growing at a CAGR of ~ 15.2 % during 2017-2023.


Key players of Global Artificial Pancreas Market:


Key players profiled in the report are Medtronic, Johnson & Johnson, Beta Bionics, Bigfoot Biomedical, Admetsys (pipeline product analysis), Animas Corporation, Defymed, dexcom, Insulet, medtech, Medtronic, Semma Therapeutics, Tandem Diabetes Care, TypeZero Technologies, and others.


Intended Audience



  • Global Artificial Pancreas, manufacturers & suppliers

  • Research and development (R&D) companies

  • Market research and consulting service providers

  • Academic institutes and universities


Segments:


The global artificial pancreas market is segmented on the basis of type and end users. Based on type, the market has been segmented as threshold suspend device system, non-threshold suspend device system, control-to-range (CTR) system, and control-to-target (CTT) system. Based on the treatment type, the market has been segmented as insulin only, bi-hormonal, and hybrid. Based on the end users, the market has been segmented as hospitals and clinics, research, and others.


Figure 1         Global Artificial Pancreas Market by End Users, 2016 (% Market Share) Artificial Pancreas Market by End Users, 2016


Regional analysis


US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. The faster market uptake of new technology in the US is also an important driver of the market for global artificial pancreas. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is expected to have the most potential which is estimated to be led by China and India. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa are expected to be a laggard due to poor economic and political conditions and poor healthcare penetration.


Study objectives:



  • To provide a detailed analysis of the market structure along with estimated future growth forecast for the next six years about various segments and sub-segments of the global Artificial Pancreas market.

  • To provide insights about factors affecting the market growth.

  • To analyze the global Artificial Pancreas market based on various factors - Price Analysis, Supply Chain Analysis, Porters Five Force analysis etc.

  • To provide past and estimated future revenue of the market’s segments and sub-segments with respect to four main geographies and their countries - the Americas, Europe, Asia Pacific along with Middle East & Africa.

  • To provide country level analysis of the market with respect to the current market size and future growth prospects.

  • To provide country level analysis of the market which includes segmentation by type, treatment type and end users.

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape of the market.

  • To track and analyze developments which are competitive in nature such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments that are currently taking place in the global artificial pancreas markets.


Research methodology Research methodology artificial pancreas markets
The report for Global Artificial Pancreas Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2023: USD 360 Million
  • 2027: Significant Value
  •   CAGR   15.2 % (2017-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type and End users
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Medtronic, Johnson & Johnson, Beta Bionics, Bigfoot Biomedical, Admetsys (pipeline product analysis), Animas Corporation, Defymed, dexcom, Insulet, medtech, Medtronic, Semma Therapeutics, Tandem Diabetes Care, TypeZero Technologies, and others
      Key Market Opportunities

  • Companies are focusing more into research and development to introduce quality
  • Advance treatment to the affected population
  •   Key Market Drivers

  • Increase in the population suffering with diabetes
  • Advancement in technology


  • Table of Contents


    1. INTRODUCTION

    1.1 DEFINITION

    1.2 SCOPE OF STUDY

    1.2.1 RESEARCH OBJECTIVE

    1.2.2 ASSUMPTIONS & LIMITATIONS

    1.2.2.1 ASSUMPTIONS

    1.2.2.2 LIMITATIONS

    1.3 MARKET STRUCTURE:

    2. RESEARCH METHODOLOGY

    2.1 RESEARCH PROCESS:

    2.2 PRIMARY RESEARCH

    2.3 SECONDARY RESEARCH:

    3. MARKET DYNAMICS

    3.1 DRIVERS

    3.2 RESTRAINTS

    3.3 OPPORTUNITIES

    3.4 MACROECONOMIC INDICATORS

    4. MARKET FACTOR ANALYSIS

    4.1 PORTERS FIVE FORCES MODEL

    4.2 BARGAINING POWER OF SUPPLIERS

    4.3 BARGAINING POWER OF BUYERS

    4.4 THREAT OF NEW ENTRANTS

    4.5 THREAT OF SUBSTITUTES

    4.6 INTENSITY OF RIVALRY

    5. GLOBAL ARTIFICIAL PANCREAS MARKET, BY CONTROL TYPE

    5.1 THRESHOLD SUSPEND DEVICE SYSTEM

    5.2 NON-THRESHOLD SUSPEND DEVICE SYSTEM

    5.3 CONTROL-TO-RANGE (CTR) SYSTEM

    5.4 CONTROL-TO-TARGET (CTT) SYSTEM

    6. GLOBAL ARTIFICIAL PANCREAS MARKET, BY TREATMENT TYPE

    6.1 INSULIN ONLY

    6.2 BI-HORMONAL

    6.3 HYBRID

    7. GLOBAL ARTIFICIAL PANCREAS MARKET, BY END USERS

    7.1 HOSPITALS AND CLINICS

    7.2 RESEARCH

    7.3 OTHERS

    8. GLOBAL ARTIFICIAL PANCREAS MARKET, BY REGION

    8.1 NORTH AMERICA

    8.1.1 INTRODUCTION

    8.2 EUROPE

    8.2.1 INTRODUCTION

    8.3 ASIA-PACIFIC

    8.3.1 INTRODUCTION

    8.4 MIDDLE EAST & AFRICA

    8.4.1 INTRODUCTION

    9. COMPETITIVE LANDSCAPE

    9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS

    9.1.1 STRATEGIC PARTNERSHIP

    9.1.2 MERGER & ACQUISITION

    10. COMPANY PROFILE

    10.1 MEDTRONIC

    10.1.1 OVERVIEW

    10.1.2 PRODUCT OVERVIEW

    10.1.3 FINANCIALS

    10.1.4 KEY DEVELOPMENTS

    10.2 JOHNSON & JOHNSON

    10.2.1 OVERVIEW

    10.2.2 PRODUCT OVERVIEW

    10.2.3 FINANCIALS

    10.2.4 KEY DEVELOPMENTS

    10.3 BETA BIONICS

    10.3.1 OVERVIEW

    10.3.2 PRODUCT OVERVIEW

    10.3.3 FINANCIALS

    10.3.4 KEY DEVELOPMENT

    10.4 BIGFOOT BIOMEDICAL

    10.4.1 OVERVIEW

    10.4.2 PRODUCT OVERVIEW

    10.4.3 FINANCIALS

    10.4.4 KEY DEVELOPMENTS

    10.5 ADMETSYS (PIPELINE PRODUCT ANALYSIS)

    10.5.1 OVERVIEW

    10.5.2 PRODUCT OVERVIEW

    10.5.3 FINANCIALS

    10.5.4 KEY DEVELOPMENTS

    10.6 ANIMAS CORPORATION

    10.6.1 OVERVIEW

    10.6.2 PRODUCT OVERVIEW

    10.6.3 FINANCIALS

    10.6.4 KEY DEVELOPMENTS

    10.7 DEFYMED

    10.7.1 OVERVIEW

    10.7.2 PRODUCT OVERVIEW

    10.7.3 FINANCIALS

    10.7.4 KEY DEVELOPMENTS

    10.8 DEXCOM

    10.8.1 OVERVIEW

    10.8.2 PRODUCT OVERVIEW

    10.8.3 FINANCIALS

    10.8.4 KEY DEVELOPMENTS

    10.9 INSULET

    10.9.1 OVERVIEW

    10.9.2 PRODUCT OVERVIEW

    10.9.3 FINANCIALS

    10.9.4 KEY DEVELOPMENTS

    10.10 SEMMA THERAPEUTICS

    10.10.1 OVERVIEW

    10.10.2 PRODUCT OVERVIEW

    10.10.3 FINANCIALS

    10.10.4 KEY DEVELOPMENTS

    10.11 TYPEZERO TECHNOLOGIES

    10.11.1 OVERVIEW

    10.11.2 PRODUCT OVERVIEW

    10.11.3 FINANCIALS

    10.11.4 KEY DEVELOPMENTS

    10.12 TANDEM DIABETES CARE

    10.12.1 OVERVIEW

    10.12.2 PRODUCT OVERVIEW

    10.12.3 FINANCIALS

    10.12.4 KEY DEVELOPMENTS

    10.8 MEDTECH

    10.13.1 OVERVIEW

    10.13.2 PRODUCT OVERVIEW

    10.13.3 FINANCIALS

    10.13.4 KEY DEVELOPMENTS

    10.14 OTHERS


    CONCLUSION


    11.1 KEY FINDINGS

    11.1.1 FROM CEO’S VIEWPOINT

    11.1.2 UNMET NEEDS OF THE MARKET

    11.2 KEY COMPANIES TO WATCH

    11.3 PREDICTION OF ARTIFICIAL PANCREAS INDUSTRY

    12. APPENDIX